TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Safety and tolerability of itacitinib
Endpoint domain: Adverse events/effects
Primary endpoint: Mean percent change from baseline in static Physician's Global Assessment (sPGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway macrophage uptake of inhaled particulate matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: difference in systolic blood pressure between sitting and standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite performance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment of gene-corrected autologous hematopoietic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Betamethasone concentration in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptom distress over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pink Esthetic Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: late death
Endpoint domain: Mortality/survival
Primary endpoint: redo operation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Grade 2 or Grade 3 Fever, Vomiting or Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Recruited, Consented, Enrolled, and Completed the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Study Duration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serum concentrations of alirocumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular related serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of coronary artery lesions (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of patients with excellent tumoral response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 12-month medication discontinuation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 12-month adherence rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in reproducibility of respiratory-related tumour motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Patients Reporting Adequate Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Abnormal Clinically Significant Vital Signs in Cohort 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings in Cohort 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Abnormal Clinically Significant Laboratory Values in Cohort 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Adverse Events (AEs) in Cohort 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Procedure and/or Device Related Stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Improvement From Baseline In Mean NRS Average Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detrusor underactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bladder outlet obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urine albumin excretion rate (UAER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: All-cause in-hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Relative risk of receiving best practices in the ICU
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Behavioral Response (Cognitive Control Task)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral Response (Language Task)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of Venous Thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity level in heart failure patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac rehabilitation barriers in heart failure patients
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Disposition for changes in life habits
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Daily drug consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the Severity of Alopecia Tool (SALT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: proportion of severe toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: ADHD Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive Functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Socioemotional Development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fine Motor Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: (Z-)endoxifen plasma concentration > 32 nM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supervised gait performance normal gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unsupervised gait performance normal gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supervised gait performance dual task gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary efficacy failure
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of chronic HBV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total intraoperative fluids required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in bloating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Accuracy of real-time chest ultrasonographic in assessing chest wall invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of the overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Respiratory function test evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Assessment of the performance status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of individual mutated genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenoma Per Colonoscopy (APC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adenoma Per Extraction (APE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Carbamylated-HDL levels alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Stone Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Amount of Urinary Leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Frequency of Daily Urinary Leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Manual Muscle Testing Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: IBM-Functional rating scale (IBM-FRS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physician Global Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI damage assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-Reactive Protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting >=50% Reduction in GERD-HRQL Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants Reporting Normalization or >=50% Reduction in Total Distal Acid Exposure Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Experiencing Serious Device and/or Procedure Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: BMI in kg/m^2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage excess weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of keratoconus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Attendance at all TEAS sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total pounds of weight lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Colonoscopy Completion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Population Level Adenoma Detection Rate (ADR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Change in Monthly Average Number of Migraine Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+ decline (slope)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to AIDS
Endpoint domain: Mortality/survival
Primary endpoint: Relaxin (RLX) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change of outer arteriolar diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: change of inner arteriolar diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Hormone response to hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Symptom response to hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in derived Modified Ashworth Scale-Bohannon (MAS) ankle score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Global Impression of Change Scale (GICS) assessed by physician
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of treatment emergent adverse events [TEAEs]
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-HPV seropositivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: diet and physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: substance use
Endpoint domain: Adverse events/effects
Primary endpoint: Transfer of iron to the fetus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiac Abnormalities As Measured By Cardiac MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac Abnormalities As Measured By Echocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Trace element levels in blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Agmatine levels in blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Telomerase levels in blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with hospitalization for worsening of heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Patients With Therapeutic Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Permanent Catheter Occlusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 28-Day All-cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: On-Treatment Serious Major Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Outcome Measure
Endpoint domain: General outcomes
Primary endpoint: Rate of change of seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Status of tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Abdominal adipose tissue variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number needed to excise (NNE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RCM diagnostic sensibility and sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of eclamptic seizure(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Six Minute Walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of episodes of hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: episodes of systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Time for Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAMD17 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dumping syndrome severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incremental area under the curve of EPA + DHA proportion in plasma phospholipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treadmill exercise duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic Healing of Erosive Esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of infant feeds from breastmilk versus formula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Food security
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in macrophages activation after single Cocarnit administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in macrophages activation after 30-days Cocarnit administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in the proportion of risky drinkers measured by AUDIT-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the severity of alcohol use according to AUDIT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction of Discharge Criteria
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rapid diagnosis of rare NMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of NMD biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of diagnosis of premalignant and malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With at Least a 1-Point Improvement in Both Temples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity of the enhanced trunk marker set for spinal kinematics measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of the enhanced trunk marker set for spinal kinematics measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in spinal kinematics between scoliosis patients and healthy adolescents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readiness for Living Donor Kidney Transplantation (LDKT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bayley Scales of Infant and Toddler Development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Participation rates in organized breast cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost by screened woman
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC of FGF23
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of clinical relevant bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection rate of new hyper-intense DWI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Sleep Quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective Alertness via Karolinska Sleepiness Scale (KSS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent change in fasting TG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic accuracy for MTB detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for RIF/INH detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time from initial clinic visit with cancer symptom/sign to entry into oncology care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Modified Motor Assessment Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of venous pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of calcitonin-gene-related peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of substance P
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Non-Traumatic Acute Low Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With New Grade 3 or Greater Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Cell-associated HIV-1 RNA in CD4+ T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effectiveness of self administered electronic tutorial
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Plasma A1C Levels at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline propensity for conscious motor processing upon completion of training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine levels in blister fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: COVID-19 Disease Incidence Rate (Symptomatic Infections Per Month)
Endpoint domain: Mortality/survival
Primary endpoint: COVID-19 Related Hospitalization Rate Due to SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Case (Disease) Fatality Risk (Percent) Due to SARS-CoV-2
Endpoint domain: Mortality/survival
Primary endpoint: Change in clinical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in activation pattern in fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in locus of control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Total PANSS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomic assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Shoulder and Elbow Surgeons (ASES) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acromiohumeral distance (AHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Opiate Withdrawal Scale (COWS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy father-child involvement and bond
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Healthy co-parenting relationship
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Development of self as father
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances